

CORPORATE AND ECONOMY NEWS

- **Godrej Consumer Products Q4 FY22 (Consolidated, YoY):** Revenue up 7% at Rs 2915.82 crore. EBITDA fell 15% at Rs 467.58 crore. EBITDA margin 16% vs 20.1%. Net profit fell 1% at Rs 363.24 crore.
- **Gland Pharma Q4 FY22 (Consolidated, YoY):** Revenue up 24% at Rs 1,103 crore. EBITDA up 6% to Rs 348 crore. EBITDA margin at 31.6% vs 36.9%. Net profit up 10% to Rs 286 crore.
- **Ashok Leyland Q4 FY22 (Consolidated, YoY):** Revenue up 22% at Rs 9,926.97 crore. EBITDA up 17.8% at Rs 1,194.11 crore. EBITDA margin 12.03% vs 12.45%. Net profit fell 60.22% at Rs 140.24 crore. Exceptional loss stood at Rs 236.91 crore. Recommended dividend of Rs 1 per share.
- **Container Corporation of India Q4 FY22 (Consolidated, YoY):** Revenue up 5.16% at Rs 2,057.56 crore. EBITDA up 112.53% at Rs 415.84 crore. EBITDA margin 20.21% vs 10%. Net profit up 900% at Rs 257.56 crore. Recommended final dividend of Rs 3 per share.
- **HPCL Q4 FY22 (Consolidated, YoY):** Revenue up 30.4% at Rs 97,288.11 crore. EBITDA down 58.86% at Rs 1,825.53 crore. EBITDA margin at 1.74% vs 5.22%. Net profit down 34% at Rs 2,018.45 crore. Recommended final dividend of Rs 14 per share.
- **Krishna Institute of Medical Sciences Q4 FY22 (Consolidated, QoQ):** Revenue down 5.4% at Rs 372.33 crore. EBITDA down 12.5% at Rs 113.56 crore. EBITDA margin at 30.5% vs 32.97%. Net profit down 0.6% at Rs 80.68 crore.
- **Endurance Technologies Q4 FY22 (Consolidated, QoQ):** Revenue up 10.04% at Rs 2,078.79 crore. EBIT up 42.16% at Rs 159.01 crore. EBIT margin at 7.65% vs 5.92%. Net profit up 44% at Rs 136.18 crore. Recommended dividend of Rs 6.25 per share.
- **Chambal Fertilisers & Chemicals Q4 FY22 (Consolidated, YoY):** Revenue up 101.5% at Rs 3,307.37 crore. EBITDA up 26.55% at Rs 361.43 crore. EBITDA margin 10.93% vs 17.41%. Net profit down 45.62% at Rs 243.57 crore. Recommended final dividend of Rs 3 per share.
- **Biocon:** The pharmaceutical player said its arm Biocon Biologics and Viatrix Inc have launched their biosimilar product -- Abevmy (bBevacizumab) -- in Canada for use in treatment of cancer. Abevmy, co-developed by Biocon Biologics and Viatrix, is a biosimilar to Roche's Avastin (Bevacizumab) and has been approved by Health Canada across four oncology indications.
- **Wipro:** The IT major has launched its new innovation studio at Austin in Texas, US, the company said. Wipro said that the new centre, spread over 40,000 square feet, will create hundreds of jobs locally.
- **Elgi Equipments:** The leading air-compressor manufacturers launched high performance, energy-efficient, and reliable electric and diesel portable air compressors.
- **Equitas Small Finance Bank:** The Founder and CEO of the private lender PN Vasudevan has asked the lender to look for his successor as he wants to hang up his boots to pursue "a distinct set of goals". He is also the Managing Director of Equitas, which began as a micro finance institution in 2007 and was later converted into the bank in 2016.
- **Hindustan Aeronautics:** The company has been granted the type certification of first Indigenous Light Transport civil passenger aircraft.
- **Key Earnings Today:** NTPC, Indigo Paints, Thermax, IDFC, Sobha, Pfizer, Nuvoco Vistas Corporation, Metro Brands, C.E. Infosystems, Indiabulls Housing Finance, JK Tyres and Industries, Hindustan Foods, Heidelberg Cement, Amara Raja Batteries, ZF Commercial Vehicle Control Systems, and Advanced Enzyme Technologies.

Source: Bloombergquint, Economic Times, Business Standard, Business Line, Times of India, Mint, Indian Express, Business Today, Indian Express, Money Control, in.investing, Cnbctv18.

MARKET SCAN

INDIAN INDICES

Index	Clsq	Chg
Sensex	52792	-2.61%
Nifty	15809	-2.65%
Bank Nifty	33316	-2.48%
IND VIX	24.56	10.15%

GLOBAL INDICES

DJIA	31,253	-0.75%
Nasdaq	11,389	-0.26%
FTSE	7,303	-1.82%
CAC	6,273	-1.26%
DAX	13,882	-0.90%
Nikkei	26,706	1.15%
Hang Seng	20,476	1.77%

Source: in.investing.com; As on 8.20 am IST

SECTOR INDEX (NSE)

IT	28352	-5.74%
Infra	4701	-2.01%
Energy	25840	-1.81%
FMCG	37740	-0.65%
Pharma	12601	-2.18%
Auto	10618	-2.67%
Metals	5476	-4.08%
Midcap	27272	-2.99%
Nifty 500	13551	-2.64%

DII/FII INVESTMENT (IN.CR.)

FII/FPI	-4899.92
DII	3225.54

Top Open Interest Gainers

Stock	OI Chg	Price Chg
ADANI PORTS	17%	-3.49%
CUB	12%	0.16%
ASTRAL	10%	-4.97%
HDFCAMC	9%	-3.86%

Top Open Interest Losers

ITC	-16%	3.04%
COROMANDEL	-8%	-2.54%
DELTACORP	-7%	-0.11%
PERSISTENT	-6%	-6.44%

FOREX MARKET

USDINR	77.46	0.03%
EURINR	81.80	-0.18%

COMMODITY MARKET

Gold (\$/OZ)	1,835	-0.34%
Silver(\$/OZ)	21.81	-0.47%
Brent (\$/Bbl)	110.5	-1.32%
Copper(\$/Lbs)	4.254	-0.53%

Source: in.investing.com; As on 8.20 am IST

GLOBAL MARKETS

Global Market Update

Wall Street ended lower after a volatile session on Thursday, with Cisco Systems slumping after giving a dismal outlook, while investors fretted about inflation and rising interest rates. The S&P 500 declined 0.58% to end the session at 3,900.79 points. The Nasdaq declined 0.26% to 11,388.50 points, while the Dow Jones Industrial Average declined 0.75% to 31,253.13 points.

Crude Oil

Oil prices were little changed on Friday as worries about weaker economic growth offset expectations that crude demand could rebound in China as Shanghai lifts some coronavirus lockdowns. Brent futures for July delivery fell 36 cents, or 0.3 percent, to \$111.68 a barrel by 0015 GMT, while US West Texas Intermediate (WTI) crude fell 36 cents, or 0.3 percent, to \$111.85 on its last day as the front-month.

SGX Nifty: Trends on SGX Nifty indicate a gap-up opening for the broader index in India with a gain of 223 points. The Nifty futures were trading around 16,008 levels on the Singaporean exchange.

TECHNICAL VIEW

Nifty Outlook:

Nifty opened gap down on Thursday at 15917, made a high of 15987, made a low of 15775, and closed on a negative note at 15809 levels. For the day, support for the Nifty exists at 15700 and 15600 levels, whereas resistance for the Nifty stands at 16000 and 16200 levels.

Bank Nifty Outlook:

Bank Nifty opened gap down on Thursday at 33461, made a high of 33634, made a low of 33181, and closed on a negative note at 33316 levels. For the day, support for Bank Nifty exists at 33000 and 32800 levels, whereas resistance for Bank Nifty stands at 33500 and 34000 levels.

DERIVATIVES INDICATORS

		NIFTY OPTIONS ACTIVITY (26-MAY SERIES)	
NIFTY	15809.40 (-430.90) (-2.65%)		
NIFTY MAY FUT	15769.45 (39.95 Points Discount)	CALL	16000 CE +42.61 lac Shares
NIFTY PCR - OI	0.80 (-0.07)	CALL	16100 CE +42.39 lac Shares
NIFTY OI (Total)	1.30 Cr. (+7.99%)	PUT	15800 PE +28.59 lac Shares
INDIA VIX	24.56 (+10.15%)	PUT	15500 PE +21.00 lac Shares
BANKNIFTY	33315.65 (-2.48%)		
BANKNIFTY MAY FUT	33274.30 (41.35 Points Discount)		
BANKNIFTY OI (Total)	28.88 Lakh (+0.02%)		

FII DERIVATIVES STATISTICS (In Cr.)

INDEX FUTURES	-920.77
INDEX OPTIONS	16904.05
STOCK FUTURES	43.77
STOCK OPTIONS	-22.23

Securities in Ban for Trade Date 20-May-2022: IBULHSGFIN, PNB, GNFC, DELTACORP

Retail Research Technical & Fundamental Calls for the Month of May-2022

Positional Calls (For 1-3 Months)

Date	Company	Rec	Rec Price	Stop Loss	Target	Status	Net Returns%
19-Oct	ITC	Buy	230-251	198	320-340	Part Booked	15.35%
31-Mar	KEC	Buy	367-371	348	420-450	Part Booked	6.42%
06-May	BEL	Buy	226-230	206	250-275	Open	
9-May	ICICIBANK	Buy	700-710	670	750-780	Open	
9-May	REDINGTON	Buy	137-139	129	150-155	Part Booked	3.65%
13-May	KNRCON	Buy	232-235	220	250-260	Open	
18-May	JKCEMENT	Buy	2375-2395	2230	2600-2700	Open	
19-May	BAJFINANCE	Buy	5650-5700	5400	6000-6200	Open	
19-May	BHARTIARTL	Buy	677-685	635	750-780	Open	

Investment Idea (For Long Term)

Date	Company	Rec	Rec Price	Target	Status	Returns%
11 Oct 21	FILATEX	Accu	115-120	145	Open	
12 Oct 21	GSPL	Accu	310-320	380	Open	
12 Oct 21	IRCON	Accu	45-46	56	Open	
14 Feb 22	KPRMILL	Accu	630-640	764	Open	
21 Feb 22	KIMS	Accu	1245-1265	1510	Open	
19 Apr 22	VTL	Accu	440-450	553	Open	

For More Information on Retail Research Products please visit <https://www.investmentz.com/research-services>

Asit C. Mehta

INVESTMENT INTERMEDIATES LTD.

Email: retailresearch@acm.co.in

Research Analyst Registration Number:

INH000002483

CIN: U65990MH1993PLC075388

Download Investmentz app:



Follow us on:



Information pertaining to Asit C. Mehta Investment Intermmediates Limited (ACMIIL):

ACMIIL is a SEBI registered Stock Broker, Merchant Banker, Portfolio Manager and Depository Participant. It is also a AMFI registered Mutual Fund Distributor. It does not have any disciplinary history. Its associate/group companies are Asit C. Mehta Commodity Services Limited, Asit C. Mehta Realty Services Pvt. Ltd, Asit C. Mehta Forex Pvt. Ltd, Nucleus IT Enabled Services, Asit C. Mehta Financial Services Limited (all providing services other than stock broking, merchant banking and portfolio management services.).

Disclosures

ACMIIL/its associates and its Research analysts have no financial interest in the companies covered on the report. ACMIIL/its associates and Research analysts did not have actual/beneficial ownership of one per cent or more in the companies being covered at the end of month immediately preceding the date of publication of the research report. ACMIIL/its associates or Research analysts have no material conflict of interest, have not received any compensation/benefits for any reason (including investment banking/ merchant banking or brokerage services) from either the companies concerned/third parties with respect to the companies covered in the past 12 months. ACMIIL/its associates and research analysts have neither managed or co-managed any public offering of securities of the companies covered nor engaged in market making activity for the companies being covered. Further, the companies covered neither are/nor were a client during the 12 months preceding the date of the research report. Further, the Research analyst/s covering the companies covered herein have not served as an officer/director or employee of the companies being covered

Disclaimer:

This report is based on information that we consider reliable, but we do not represent that it is accurate or complete and it should not be relied upon such. ACMIIL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the report. To enhance transparency we have incorporated a Disclosure of Interest Statement in this document. This should however not be treated as endorsement of the views expressed in the report.

You are also requested to refer to the disclaimer (which is deemed to be part and parcel and is applicable to this research report as well) : <http://www.investmentz.com/disclaimer>